This systematic literature review explores the role of smart contracts in improving data sharing for drug development, with an emphasis on security and transparency. Using blockchain technology, smart contracts offer a decentralized tracking mechanism for pharmaceutical supply chains, addressing challenges related to drug authentication and supply chain optimization. The review examined 52 studies using the PRISMA methodology, highlighting the automation of data exchange, reduced reliance on external parties, and acceleration of operational processes. Advanced encryption and strict access controls in smart contracts strengthen data security, ensuring patient confidentiality and compliance with medical data regulations. Despite technical and regulatory barriers, smart contracts promise significant improvements in operational efficiency, transparency, and collaboration among stakeholders in drug development. This study emphasizes the need for standardized protocols, further empirical research, and strategic implementation to fully leverage the potential of smart contracts in the pharmaceutical industry. Integration of these technologies can accelerate clinical trials and improve data reliability, thereby enhancing the safety and effectiveness of the drug development process.
Copyrights © 2024